The pivotal role of timing of intravenous thrombolysis bridging treatment prior to endovascular thrombectomy

被引:0
作者
Molad, Jeremy [1 ]
Hallevi, Hen [2 ,3 ]
Seyman, Estelle [2 ]
Ben-Assayag, Einor [2 ,3 ]
Jonas-Kimchi, Tali [4 ]
Sadeh, Udi
Rotschild, Ofer [2 ]
Simaan, Naaem [5 ]
Horev, Anat [6 ]
Cohen, Jose [7 ]
Leker, Ronen R. [8 ]
Honig, Asaf [6 ]
机构
[1] Tel Aviv Sourasky Med Ctr, Dept Stroke & Neurol, 6 Weizmann St, IL-64239 Tel Aviv, Israel
[2] Tel Aviv Sourasky Med Ctr, Dept Stroke & Neurol, Tel Aviv, Israel
[3] Tel Aviv Univ, Fac Med, Tel Aviv, Israel
[4] Tel Aviv Sourasky Med Ctr, Dept Radiol, Tel Aviv, Israel
[5] Ziv Med Ctr, Dept Neurol, Safed, Israel
[6] Soroka Med Ctr, Dept Neurol, Beer Sheva, Israel
[7] Hadassah Hebrew Univ Med Ctr, Dept Neurosurg, Jerusalem, Israel
[8] Hadassah Hebrew Univ Med Ctr, Dept Neurol, Jerusalem, Israel
关键词
bridging treatment; endovascular thrombectomy; thrombolysis; ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; MECHANICAL THROMBECTOMY; STATIN PRETREATMENT; ALTEPLASE; THERAPY; TRIAL; MANAGEMENT; OUTCOMES; ECASS;
D O I
10.1177/17562864231216637
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The role of intravenous thrombolysis (IVT) as bridging treatment prior to endovascular thrombectomy (EVT) is under debate and better patient selection is needed. Objectives: As the efficacy and safety of IVT diminish with time, we aimed to examine the impact of bridging treatment within different time frames from symptom onset. Design: A retrospective registry study. Methods: Data were extracted from ongoing prospective EVT registries in two large tertiary centers. The current study included IVT-eligible patients with onset to door (OTD) < 4 h. We examined the efficacy and safety of bridging treatment through a comparison of the IVT + EVT group with the direct-EVT group by different time frames. Results: In all, 408 patients (age 71.1 +/- 14.6, 50.6% males) were included, among them 195 received IVT + EVT and 213 underwent direct EVT. Both groups had similar characteristics. In the IVT + EVT group only, longer OTD was associated with lower rates of favorable outcome (p = 0.021) and higher rates of hemorrhagic transformation (HT; p = 0.001). In patients with OTD <= d2 h, IVT + EVT compared to direct EVT had higher rates of TICI 2b-3 (86.2% versus 80.7%, p = 0.038). In patients with OTD > 2 h, IVT + EVT had lower rates of favorable outcome (33.3% versus 56.9%, p = 0.021), worse discharge National Institutes of Health Stroke Scale [7 (2-13) versus 3 (1-8), p = 0.024], and higher rates of HT (34.0% versus 8.5%, p < 0.001). Discussion: In this study, we found OTD times to have a significant effect on the impact of IVT bridging treatment. Our study shows that among patients with OTD < 2 h bridging treatment may be associated with higher rates of successful recanalization. By contrast, in patients with OTD > 2 h, bridging treatment was associated with worse outcomes. Further time-sensitive randomized trials are needed.
引用
收藏
页数:13
相关论文
共 38 条
  • [1] CLASSIFICATION OF SUBTYPE OF ACUTE ISCHEMIC STROKE - DEFINITIONS FOR USE IN A MULTICENTER CLINICAL-TRIAL
    ADAMS, HP
    BENDIXEN, BH
    KAPPELLE, LJ
    BILLER, J
    LOVE, BB
    GORDON, DL
    MARSH, EE
    KASE, CS
    WOLF, PA
    BABIKIAN, VL
    LICATAGEHR, EE
    ALLEN, N
    BRASS, LM
    FAYAD, PB
    PAVALKIS, FJ
    WEINBERGER, JM
    TUHRIM, S
    RUDOLPH, SH
    HOROWITZ, DR
    BITTON, A
    MOHR, JP
    SACCO, RL
    CLAVIJO, M
    ROSENBAUM, DM
    SPARR, SA
    KATZ, P
    KLONOWSKI, E
    CULEBRAS, A
    CAREY, G
    MARTIR, NI
    FICARRA, C
    HOGAN, EL
    CARTER, T
    GURECKI, P
    MUNTZ, BK
    RAMIREZLASSEPAS, M
    TULLOCH, JW
    QUINONES, MR
    MENDEZ, M
    ZHANG, SM
    ALA, T
    JOHNSTON, KC
    ANDERSON, DC
    TARREL, RM
    NANCE, MA
    BUDLIE, SR
    DIERICH, M
    HELGASON, CM
    HIER, DB
    SHAPIRO, RA
    [J]. STROKE, 1993, 24 (01) : 35 - 41
  • [2] Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging
    Albers, G. W.
    Marks, M. P.
    Kemp, S.
    Christensen, S.
    Tsai, J. P.
    Ortega-Gutierrez, S.
    McTaggart, R. A.
    Torbey, M. T.
    Kim-Tenser, M.
    Leslie-Mazwi, T.
    Sarraj, A.
    Kasner, S. E.
    Ansari, S. A.
    Yeatts, S. D.
    Hamilton, S.
    Mlynash, M.
    Heit, J. J.
    Zaharchuk, G.
    Kim, S.
    Carrozzella, J.
    Palesch, Y. Y.
    Demchuk, A. M.
    Bammer, R.
    Lavori, P. W.
    Broderick, J. P.
    Lansberg, M. G.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (08) : 708 - 718
  • [3] MEASUREMENTS OF ACUTE CEREBRAL INFARCTION - A CLINICAL EXAMINATION SCALE
    BROTT, T
    ADAMS, HP
    OLINGER, CP
    MARLER, JR
    BARSAN, WG
    BILLER, J
    SPILKER, J
    HOLLERAN, R
    EBERLE, R
    HERTZBERG, V
    RORICK, M
    MOOMAW, CJ
    WALKER, M
    [J]. STROKE, 1989, 20 (07) : 864 - 870
  • [4] Combined intravenous and endovascular treatment versus primary mechanical thrombectomy. The Italian Registry of Endovascular Treatment in Acute Stroke
    Casetta, Ilaria
    Pracucci, Giovanni
    Saletti, Andrea
    Saia, Valentina
    Padroni, Marina
    De Vito, Alessandro
    Inzitari, Domenico
    Zini, Andrea
    Vallone, Stefano
    Bergui, Mauro
    Cerrato, Paolo
    Bracco, Sandra
    Tassi, Rossana
    Gandini, Roberto
    Sallustio, Fabrizio
    Piano, Mariangela
    Motto, Cristina
    La Spina, Paolino
    Vinci, Sergio L.
    Causin, Francesco
    Baracchini, Claudio
    Gasparotti, Roberto
    Magoni, Mauro
    Castellan, Lucio
    Serrati, Carlo
    Mangiafico, Salvatore
    Toni, Danilo
    [J]. INTERNATIONAL JOURNAL OF STROKE, 2019, 14 (09) : 898 - 907
  • [5] Combined Intravenous Thrombolysis and Thrombectomy vs Thrombectomy Alone for Acute Ischemic Stroke A Pooled Analysis of the SWIFT and STAR Studies
    Coutinho, Jonathan M.
    Liebeskind, David S.
    Slater, Lee-Anne
    Nogueira, Raul G.
    Clark, Wayne
    Davalos, Antoni
    Bonafe, Alain
    Jahan, Reza
    Fischer, Urs
    Gralla, Jan
    Saver, Jeffrey L.
    Pereira, Vitor M.
    [J]. JAMA NEUROLOGY, 2017, 74 (03) : 266 - 272
  • [6] Asymptomatic hemorrhage after thrombolysis may not be benign - Prognosis by hemorrhage type in the Canadian Alteplase for Stroke Effectiveness Study registry
    Dzialowski, Imanuel
    Pexman, J. H. Warwick
    Barber, Philip A.
    Demchuk, Andrew M.
    Buchan, Alastair M.
    Hill, Michael D.
    [J]. STROKE, 2007, 38 (01) : 75 - 79
  • [7] Fischer U, 2022, LANCET, V400, P104, DOI 10.1016/S0140-6736(22)00537-2
  • [8] Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
    Hacke, W
    Kaste, M
    Fieschi, C
    von Kummer, R
    Davalos, A
    Meier, D
    Larrue, V
    Bluhmki, E
    Davis, S
    Donnan, G
    Schneider, D
    Diez-Tejedor, E
    Trouillas, P
    [J]. LANCET, 1998, 352 (9136) : 1245 - 1251
  • [9] HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017
  • [10] Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke
    Hacke, Werner
    Kaste, Markku
    Bluhmki, Erich
    Brozman, Miroslav
    Davalos, Antoni
    Guidetti, Donata
    Larrue, Vincent
    Lees, Kennedy R.
    Medeghri, Zakaria
    Machnig, Thomas
    Schneider, Dietmar
    von Kummer, Ruediger
    Wahlgren, Nils
    Toni, Danilo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (13) : 1317 - 1329